Johnson & Johnson is offering up access to its clinical trial data on schizophrenia as part of a new collaborative research project striving to improve understanding of the disease and find better treatments.
The US healthcare giant is linking with a group of leading research organisations* to launch the OPTICS Project, which offers a new forum for collaborative analysis of clinical trial data owned by its Janssen group with schizophrenia data from the National Institutes of Health.
The project, which also aims to create new models for conducting research, marks the first time that data about the causes of schizophrenia and data from clinical trials of therapies will be available to researchers in one place.
"OPTICS will foster open-science collaborations and lead to new, fundamental insights about schizophrenia so that we can improve therapies and treatments, and ultimately find a cure,” said Husseini Manji, Global Head, Neuroscience Therapeutic Area, at Janssen Research & Development.
The project is governed by an Advisory Board comprised of scientists from academia, the biopharmaceutical industry, and the NIMH.
*Current collaborators and members of advisory board are Yale University School of Medicine, Rutgers University, Harvard T.H. Chan School of Public Health, and the National Institute of Mental Health.